哈斯顿生物制药公司在10个月内在8个亚太国家推出了品牌药物, 在泰国获得了最高的市场份额. Hasten Biopharma launched branded drugs in 8 Asia-Pacific nations within 10 months, hitting top market shares in Thailand.

哈斯顿生物制药公司在2024年6月获得权利后,在8个亚太市场迅速建立商业平台,完成了70个营销授权,并在短短10个月内推出了品牌产品. Hasten Biopharmaceutical has rapidly established a commercial platform across eight Asia-Pacific markets, completing 70 marketing authorizations and launching branded products in just 10 months after acquiring rights in June 2024. 该公司利用DKSH等伙伴关系,在泰国的慢性病治疗 -- -- Edarbi、Madiplot和Oseni -- -- 超额目标中达到了顶级市场地位。 Leveraging partnerships like DKSH, the company achieved top market positions in Thailand for its chronic disease treatments—Edarbi, Madiplot, and Oseni—exceeding targets. 其成功来自地方战略、学术参与以及与医疗机构的合作。 Its success stems from localized strategies, academic engagement, and collaboration with medical institutions. 该公司旨在将其模式扩大到更广泛的区域保健生态系统,支持中国生物制药创新,改善患者在高增长市场中的准入。 The company aims to expand its model into a broader regional healthcare ecosystem, supporting Chinese biopharmaceutical innovation and improving patient access across high-growth markets.